| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cy5-DBCO targets azide-containing molecules for labeling via strain-promoted azide-alkyne cycloaddition (SPAAC). The DBCO group reacts with azides with high efficiency and selectivity, forming a stable triazole linkage. This bioorthogonal reaction does not require copper catalysis, making it suitable for labeling in living systems. The Cy5 fluorophore provides a bright and photostable signal for near-infrared fluorescence imaging, allowing for the detection and tracking of labeled biomolecules in vitro and in vivo.
|
|---|---|
| ln Vitro |
Without the use of a copper catalyst or high temperatures, Cy5-DBCO (DBCO-SuLfo-Cy5) combines with azide through a copper-free "click chemistry" reaction to generate a stable triazole.
In vitro, Cy5-DBCO is used to label azide-containing biomolecules, such as proteins, peptides, and nucleic acids, via SPAAC. The labeling reaction is typically performed in aqueous buffers at room temperature for 1-2 hours. The labeled biomolecules can then be analyzed by SDS-PAGE, Western blot, or fluorescence microscopy. Cy5-DBCO is also used in the synthesis of fluorescently labeled PROTACs and other conjugates for cellular imaging studies. |
| ln Vivo |
In vivo, Cy5-DBCO is used for near-infrared fluorescence imaging of azide-labeled biomolecules. The compound's excitation and emission maxima in the near-infrared range allow for deep tissue imaging with minimal background autofluorescence. Cy5-DBCO-labeled probes can be used to track the biodistribution of drugs, study protein-protein interactions, and image tumors in animal models.
|
| Enzyme Assay |
In vitro labeling assays for Cy5-DBCO involve measuring the efficiency of the reaction with azide-containing molecules. The assay is performed by incubating the compound with an azide-containing molecule in a buffer at room temperature. The reaction progress is monitored by HPLC or mass spectrometry. The labeling efficiency is calculated from the ratio of labeled to unlabeled product.
|
| Cell Assay |
In vitro cellular experiments for Cy5-DBCO are performed using cells that have been metabolically labeled with azide-containing sugars or other azide-containing molecules. The cells are treated with Cy5-DBCO, and the fluorescence signal is detected by flow cytometry or fluorescence microscopy. The labeling efficiency and cellular localization of the labeled biomolecules can be assessed.
|
| Animal Protocol |
In vivo animal studies for Cy5-DBCO are conducted using mouse models. Cy5-DBCO-labeled probes are administered via intravenous injection, and the fluorescence signal is monitored using an in vivo imaging system. The biodistribution and clearance of the probes are assessed by measuring the fluorescence intensity in various tissues.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Cy5-DBCO are determined by the properties of the conjugate to which it is attached. The small molecule itself is rapidly cleared from circulation. The fluorescence properties of Cy5 allow for the non-invasive tracking of the conjugate in vivo.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Cy5-DBCO has not been extensively characterized. As a fluorescent dye, it is generally considered to have low toxicity. However, high concentrations may cause phototoxicity or other adverse effects. Standard safety precautions should be followed when handling this compound.
|
| Additional Infomation |
See also: DBCO-Cy5 (preferred).
Cy5-DBCO is a fluorescent dye conjugate used for the labeling of azide-containing biomolecules via strain-promoted azide-alkyne cycloaddition (SPAAC). The Cy5 fluorophore provides a bright and photostable signal for near-infrared fluorescence imaging. Cy5-DBCO is a valuable tool for bioconjugation, cellular imaging, and in vivo imaging applications, enabling the detection and tracking of labeled biomolecules in complex biological systems. |
| Molecular Formula |
C52H56N4O11S3
|
|---|---|
| Molecular Weight |
1009.2163
|
| Exact Mass |
1008.31
|
| CAS # |
1564286-24-3
|
| PubChem CID |
136374347
|
| Appearance |
Blue to black solid powder
|
| LogP |
5.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
70
|
| Complexity |
2440
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC2=C(C=1)C(C)(C)C(/C=C/C=C/C=C1\C(C)(C)C3C=C(C=CC=3N\1CCCS(=O)(=O)O)S(=O)(=O)O)=[N+]2CCCCCC(NCCC(N1C2=CC=CC=C2C#CC2=CC=CC=C2C1)=O)=O)(=O)(=O)[O-]
|
| InChi Key |
LQHUKJFMCCLWEL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C52H56N4O11S3/c1-51(2)42-34-40(69(62,63)64)25-27-45(42)54(31-14-6-9-22-49(57)53-30-29-50(58)56-36-39-18-11-10-16-37(39)23-24-38-17-12-13-19-44(38)56)47(51)20-7-5-8-21-48-52(3,4)43-35-41(70(65,66)67)26-28-46(43)55(48)32-15-33-68(59,60)61/h5,7-8,10-13,16-21,25-28,34-35H,6,9,14-15,22,29-33,36H2,1-4H3,(H3-,53,57,59,60,61,62,63,64,65,66,67)
|
| Chemical Name |
1-[6-[[3-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-3-oxopropyl]amino]-6-oxohexyl]-2-[(1E,3E,5E)-5-[3,3-dimethyl-5-sulfo-1-(3-sulfopropyl)indol-2-ylidene]penta-1,3-dienyl]-3,3-dimethylindol-1-ium-5-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 10 mg/mL (~9.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9909 mL | 4.9543 mL | 9.9086 mL | |
| 5 mM | 0.1982 mL | 0.9909 mL | 1.9817 mL | |
| 10 mM | 0.0991 mL | 0.4954 mL | 0.9909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
